Investor Relations

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer.

Press Releases
Dec 12, 2022

29% CR rate observed in R/R AML patients with FLT3 mutation 22% CR/CRh rate observed in R/R AML with spliceosome mutation 45% ORR observed in R/R hrMDS patients with spliceosome mutation Curis to...

Dec 5, 2022

Curis to review results during conference call, featuring commentary by Dr. Eric Winer, M.D., Dana-Farber Cancer Institute, on Monday, December 12 at 10:00 a.m. ET LEXINGTON, Mass., Dec. 5, 2022...

View all press releases >>

Events & Presentations
Latest Presentation
Investor Alerts

Receive the latest alerts via email.

Sign up

Contact IR

Curis, Inc.
128 Spring Street
Building C- Suite 500

Lexington, MA 02421
Phone: 617-503-6500

Transfer Agent

150 Royall St., Suite 101
Canton, MA 02021
Phone: 877-810-2248

This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.